GlassScriptPhysician profile
Hrachya Paruyryan
NPI 1952505125
$6,706.20
in general payments reported to CMS, 2019-2025
42 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $844 · 2021: $1,832 · 2022: $1,535 · 2023: $698 · 2024: $699 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.10 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,099.68 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $1,081.07 | 2019-2025 | |
| Novo Nordisk INC | $757.19 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $471.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $371.53 | 2020-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $230.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.86 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.46 | 2020-2024 | Xifaxan |
| Astellas Pharma US INC | $195.62 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $162.01 | 2019-2022 | |
| Pfizer INC. | $150.58 | 2019-2024 | |
| Lilly USA, LLC | $134.87 | 2020-2025 | Mounjaro, Zepbound |
| Scilex Pharmaceuticals INC. | $133.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.22 | 2019-2023 | Verquvo |
| Sunovion Pharmaceuticals INC. | $121.27 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hrachya Paruyryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.